CRISPR Therapeutics AG - Company Profile
Powered by 
All the data and insights you need on CRISPR Therapeutics AG in one report.
$295
- Save hours of research time and resources with
our up-to-date CRISPR Therapeutics AG Strategy Report
- Understand CRISPR Therapeutics AG position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
CRISPR Therapeutics AG (CRISPR) is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a gene editing technology that allows for precise, altering specific sequences of genomic DNA. The company primarily operates in Switzerland, the UK and the US. The company conducts its business through one operating segment: the business of discovering, developing and commercializing therapies derived from or incorporating genome-editing echnology.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer